Risk factors for the recurrence in pulmonary tuberculosis patients with massive hemoptysis
The Clinical Respiratory Journal · 2023
DOI: 10.1111/crj.13653 ↗At a glance
Journal article in The Clinical Respiratory Journal, 2023. Written by Qiong Lin and 9 co-authors. Institution: Department of Respiratory Medicine, Fuzhou No.1 Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian, China. Major MEDLINE topics: Tuberculosis, Pulmonary, Embolization, Therapeutic. Cited 4 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: Fuzhou Municipal Clinical Medical Center, key Clinical Specialty Discipline Construction Program of Fuzhou, Fujian, P.R.C, Fujian Medical University.
Abstract (original language)
Objectives
To evaluate the outcomes of bronchial artery embolization (BAE) for the treatment of massive hemoptysis in patients with pulmonary tuberculosis and identify risk factors that influence recurrence.
Methods
A total of 81 patients with massive hemoptysis who underwent BAE between January 2014 and December 2017 were retrospectively reviewed. All of the patients had either a history of pulmonary tuberculosis or a current diagnosis of pulmonary tuberculosis. Follow‐up ranged from 18 to 66 months.
Results
Hemoptysis was stopped or markedly decreased, with subsequent clinical improvement in 73 patients, while 11 patients experienced recurrence during the follow‐up period. Systemic‐pulmonary shunts and clinical failure showed a statistically significant correlation with the recurrence rate. The cumulative non‐recurrence rate was 95.3% for 3 months and 81.9% for more than 24 months. Complications were common (12.5%), but self‐limiting.
Conclusions
BAE is a safe and effective treatment option for the control of massive hemoptysis in pulmonary tuberculosis patients. Systemic‐pulmonary shunts and clinical failure are the risk factors for recurrence.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Respiratory Medicine, Fuzhou No.1 Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian, China.
- Department of Intervention Therapy, Fuzhou No.1 Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian, China.
- Department of Medical Imaging, Fuzhou Second Hospital of Xiamen University (Fuzhou Second Hospital), Fuzhou, Fujian, China.
- School of Finance, Fujian Jiangxia University, Fuzhou, Fujian, China.
- Cent Lab, Fuzhou No.1 Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian, China.
ORCID profiles: Liyu Xu
Funding
- Fuzhou Municipal Clinical Medical Center
- key Clinical Specialty Discipline Construction Program of Fuzhou, Fujian, P.R.C
- Fujian Medical University
Cite
APA
Lin, Q., Chen, J., Yu, T., Gao, B., Kuang, K., Fan, Y., Xu, J., Li, X., Lin, X., & Xu, L. (2023). Risk factors for the recurrence in pulmonary tuberculosis patients with massive hemoptysis. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13653
Vancouver
Lin Q, Chen J, Yu T, Gao B, Kuang K, Fan Y, et al. Risk factors for the recurrence in pulmonary tuberculosis patients with massive hemoptysis. The Clinical Respiratory Journal. 2023. doi:10.1111/crj.13653
BibTeX
@article{Lin2023,
author = {Lin, Qiong and Chen, Jian and Yu, Tianxing and Gao, Bing and Kuang, Kaijin and Fan, Yong and Xu, Junping and Li, Xiaohua and Lin, Xin and Xu, Liyu},
title = {Risk factors for the recurrence in pulmonary tuberculosis patients with massive hemoptysis},
journal = {The Clinical Respiratory Journal},
year = {2023},
doi = {10.1111/crj.13653}
}
EUVIMED